8-K: Gilead Sciences Q2 2026: Acquisitions Drive Loss Amidst Revenue Growth

Gilead Sciences reported a substantial net loss for Q2 2026, primarily due to significant acquisition-related expenses, despite a 10% increase in total revenues driven by its base business, excluding Veklury.

Summary

• Gilead Sciences announced its financial results for the second quarter ended June 30, 2026.
• Total revenues increased by 10% year-over-year to $7.8 billion, driven by strong performance in HIV products, Trodelvy, and Livdelzi, partially offset by lower Veklury sales.
• Product sales, excluding Veklury, grew 10% to $7.6 billion.
• HIV product sales increased by 12% to $5.7 billion, with Biktarvy sales up 7% to $3.8 billion and Descovy sales up 48% to $967 million.
• The company reported a diluted loss per share of $(8.45) and a non-GAAP diluted loss per share of $(6.75).
• This loss is significantly impacted by $11.2 billion in acquired in-process research and development (IPR&D) expenses related to acquisitions of Arcellx, Tubulis, and Ouro Medicines.
• As of June 30, 2026, Gilead had $3.2 billion in cash, cash equivalents, and marketable debt securities.
• The company updated its full-year 2026 guidance, now expecting product sales between $30.1 billion and $30.4 billion, and a non-GAAP diluted loss per share between $(0.65) and $(0.30).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a negative score due to significant non-GAAP losses driven by large acquisition-related expenses, despite underlying operational revenue growth.

Positives

• Total revenues increased 10% year-over-year to $7.8 billion.
• Product sales, excluding Veklury, increased 10% to $7.6 billion.
• HIV product sales grew 12% to $5.7 billion, driven by higher average realized price and demand.
• Biktarvy sales increased 7% to $3.8 billion.
• Descovy sales saw a significant increase of 48% to $967 million.
• Trodelvy sales increased 26% to $457 million.
• Livdelzi sales increased, contributing to a 10% growth in the Liver Disease portfolio to $877 million.
• The company announced three FDA approvals and three positive Phase 3 updates.
• Full-year 2026 product sales guidance was increased to a range of $30.1 billion to $30.4 billion.
• Full-year 2026 non-GAAP diluted loss per share guidance was narrowed and improved to a range of $(0.65) to $(0.30).

Negatives

• Reported a diluted loss per share of $(8.45) for the quarter, a significant decrease from $1.56 in the prior year.
• Reported a non-GAAP diluted loss per share of $(6.75), down from $2.01 in the prior year.
• Incurred $11.2 billion in acquired IPR&D expenses related to the acquisitions of Arcellx, Tubulis, and Ouro Medicines.
• Veklury sales decreased by 81% to $23 million due to lower COVID-19 hospitalizations.
• Cell Therapy product sales decreased by 14% to $417 million due to competitive headwinds.
• Yescarta sales decreased 12% and Tecartus sales decreased 24% due to competition.
• Cash, cash equivalents, and marketable debt securities decreased to $3.2 billion from $10.6 billion at the end of the previous year, largely due to acquisition outflows.
• Full-year 2026 GAAP diluted loss per share guidance was revised to a range of $(3.75) to $(3.40), indicating an expected loss.

Risks

• The company's ability to achieve its full year 2026 financial guidance is subject to risks including the uncertainty of Veklury revenues, impacts from Medicare Part D pricing reform, expiration of Affordable Care Act subsidies, and changes in U.S. trade policies.
• Risks related to realizing the potential benefits of acquisitions, collaborations, and licensing arrangements.
• Clinical trial risks, including unfavorable results, delays, or failure to obtain regulatory approvals for product candidates.
• Potential disruptions to the manufacturing and supply chain of Gilead's products.
• Pricing and reimbursement pressures from government agencies and third parties.
• Market share and price erosion from generic versions of Gilead products.
• The risk that physicians and patients may not see advantages of Gilead's products over competing therapies.
• Regulatory risks, including potential limitations on use or withdrawal of approvals for products like Hepcludex, Trodelvy, and once-weekly oral Yeztugo.

Future Outlook

For the full year 2026, Gilead now expects product sales between $30.1 billion and $30.4 billion, and product sales excluding Veklury between $29.8 billion and $30.1 billion. Veklury sales are projected to be around $300 million. The company anticipates a GAAP diluted loss per share between $(3.75) and $(3.40), and a non-GAAP diluted loss per share between $(0.65) and $(0.30). This guidance includes the significant impact of acquired IPR&D charges.

Management Comments

• "Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi."
• "HIV sales grew 12%, reflecting continued strength in treatment and the rapid expansion of our PrEP business, supporting an increase in our base business revenue expectations for 2026."
• "We also made significant clinical progress with three FDA approvals and three positive Phase 3 updates."
• "We look forward to delivering on our many opportunities in the second half of the year including another two potential launches in oncology and HIV."

Industry Context

StockSavvy.ai notes that Gilead's Q2 2026 results reflect a common trend in the biopharmaceutical industry where significant R&D investments and strategic acquisitions, while promising for future growth, can lead to substantial short-term impacts on reported earnings. The strong performance in the HIV segment and the growth of key oncology and liver disease products demonstrate the company's ongoing operational strength, even as it navigates the financial implications of its aggressive M&A strategy.

Stakeholder Impact

• Shareholders: The significant GAAP loss and revised full-year GAAP loss guidance may negatively impact investor sentiment and stock price in the short term, despite underlying revenue growth and strategic acquisitions aimed at long-term value creation.
• Employees: Integration of acquired companies may lead to organizational changes and potential restructuring, impacting employee roles and responsibilities.
• Creditors: The decrease in cash reserves and increased liabilities due to acquisitions could be a point of consideration for creditors, although the company has also secured debt financing.
• Suppliers: Continued growth in product sales suggests ongoing demand, which is generally positive for suppliers.

Next Steps

• Focus on delivering on opportunities in the second half of the year, including two potential launches in oncology and HIV.
• Continue to advance clinical progress with ongoing R&D efforts.
• Integrate newly acquired companies and assets to realize their potential benefits.
• Manage cash flow and financial resources effectively following significant acquisition outflows.

Key Dates

Recommendation

While Gilead demonstrates strong operational revenue growth in its core HIV and oncology segments and has made significant clinical progress, the substantial GAAP and non-GAAP losses driven by massive acquisition-related IPR&D expenses create significant near-term uncertainty. The revised full-year guidance also indicates an expected loss. The strategic rationale for the acquisitions is sound for long-term growth, but the immediate financial impact warrants a cautious 'hold' stance until the integration benefits become clearer and profitability improves.

Keywords

Gilead Sciences, Q2 2026 Earnings, HIV, Oncology, Acquisitions, Arcellx, Tubulis, IPR&D